These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27146462)

  • 1. A Practical Guide to Ordering and Interpreting Coagulation Tests for Patients on Direct Oral Anticoagulants in Singapore.
    Wong WH; Yip CY; Sum CL; Tan CW; Lee LH; Yap ES; Kuperan P; Ting WC; Ng HJ
    Ann Acad Med Singap; 2016 Mar; 45(3):98-105. PubMed ID: 27146462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
    Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
    J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
    Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
    Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
    Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
    Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New - direct oral anticoagulants: actual review].
    Michalcová J; Penka M; Buliková A; Zavřelová J; Štěpařová A
    Vnitr Lek; 2016; 62(10):805-813. PubMed ID: 27900867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
    Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
    Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
    Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
    Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
    Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
    Reda S; Brügelmann A; Müller J; Oldenburg J; Pötzsch B; Rühl H
    Sci Rep; 2020 Jul; 10(1):12221. PubMed ID: 32699227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.